RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > In Focus: Risks and Rewards

In Focus: Risks and Rewards

Posted 01 September 2011 | By

The September issue of Regulatory Focus considers various systems used to assess and manage the risks and potential hazards associated with developing medical products. Monitoring risk is an essential component in both the medical device and drug development arenas. Medical device and pharmaceutical companies need to have appropriate programs in place to evaluate potential risks associated with their products as well as mechanisms (e.g., inquiries, complaints, market studies, focus groups, servicing) to capture customer feedback regarding product use.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.